"Proove Biosciences Inc. http announces a new study validating the accuracy of precision medicine technology to predict prescription opioid abuse.   This study entitled Evaluation of a Predictive Algorithm that Detects Aberrant Use of Opioids in an Addiction Treatment Centre is published in the peerreviewed Journal of Addiction Research and Therapy Impact Factor . https  Distinguished Fellow American Society of Addiction Medicine ASAM Diplomate American Board of Addiction Medicine and Fellow American College of Preventive Medicine J. Ramsay Farah MD MPH MRO CPE led a research team that showed Proove Opioid Risk identifies patients at risk for Opioid Use Disorder OUD with nearly  accuracy. This study evaluated  patients comparing  Medicaid patients at an addiction treatment facility with confirmed cases of opioid abuse and  healthy patients with no history of opioid use.  The receiving operator characteristic ROC curve had an area under the curve AUC of .. Furthermore the sensitivity of the moderate risk cutoff score was  while the specificity of the high risk score was .  Dr. Farah who serves as the Chief Medical Officer for the Phoenix Health Center in Hagerstown prior NE Regional Medical Director for United Healthcare Clinical Services and Director ASAM explains Based on ASAMs definition of addiction about half of substance abuse is due to genetic factors. This study shows that analyzing genetics with lifestyle and behavioral variables in a predictive algorithm can accurately stratify patient risk. Dr. Ashley Brenton Associate Director of RD for Proove states This validation study builds on the peerreviewed evidence supporting Proove Opioid Risk and its components as an optimal model to predict opioid abuse risk. Study author Gregory A. Smith M.D former Director of Pain Management at Harbor UCLA explains Having used this technology for  years this data provides further evidence that clinicians can use Proove Opioid Risk for ruling out patients unlikely to exhibit aberrant behaviors and identifying highrisk patients for alternative therapies. Proove Opioid Risk httpproove.com is a proprietary precision medicine profile consisting of an algorithm which analyzes  variables  genetic and  lifestyle and behavioral factors individually supported by over  peerreviewed publications. Peerreviewed clinical studies show that the Proove Opioid Risk profile accurately identifies patient risk for opioid abuse. About Proove Biosciences Proove Biosciences http is the leader in precision medicine for the condition that lies at the nexus of health  pain.  Proove delivers precision medicine solutions for the nations most prevalent and expensive health condition by investing heavily in research that has won awards from leading medical societies and been published in peerreviewed journals.  Discovered by NIHfunded scientists Proove has translated into clinical practice the genetic variants and phenotypic factors contributing to pain sensitivity and chronic pain risk. Prooves medical advisory board is led by those NIHfunded researchers and the company has licensed some of its technology from leading academic centers such as the University of North Carolina at Chapel Hill the University of Utah and other institutions.  Positioned as The Healthcare Decision Company Prooves patented technology platform combines genetic clinical environmental and lifestyle information to help clinicians better evaluate pain sensitivity assess risk for opioid use disorder predict therapeutic response to pain medications and assess drug metabolism for the many medications used in chronic pain patients.  For more information please visit  http or call toll free PROOVEBIO . SOURCE Proove Biosciences Inc. Related Links http"